<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROCORTISONE- hydrocortisone tablet </strong><br>Carilion Materials Management<br></p></div>
<h1>HYDROCORTISONE Tablets, USP Lineage Therapeutics Rx only
        <br><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ccd38b11-0971-4d53-964c-b96eba28a81c"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Hydrocortisone Tablets, USP contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract.</p>
<p>Hydrocortisone USP is white to practically white, odorless, crystalline powder with a melting point of about 215°C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.</p>
<p>The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-,(11β)-. Its molecular weight is 362.46 and the structural formula is as outlined below.</p>
<div class="Figure">
<img alt="structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d4d2912e-d1e8-4b40-af88-59c87fa12318&amp;name=hydrocortisone-tablets-1.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Hydrocortisone Tablets, USP are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone. Inactive ingredients: lactose, pregelatinized corn starch, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0efd469d-83cf-4dda-9a46-6b5860917ded"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">ACTIONS</span></h1>
<p class="First">Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.</p>
<p>Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_4abfe049-c6c5-4ddd-9385-e335d8f60cd5"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Hydrocortisone Tablets are indicated in the following conditions.</p>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_af2932ad-7c47-44cf-b7f4-df3ba0389ba8"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></h2>
<p class="First">Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> Non suppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span> <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> associated with cancer
                                    <br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_9c0fd1b3-1697-494f-bb37-0841a2c093ce"></a><a name="section-3.2"></a><p></p>
<h2><span class="Bold">2. Rheumatic Disorders</span></h2>
<p class="First">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<p><span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span> <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy) <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span> Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span> Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span> Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span>
                                    <br><br><br><br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_8ab31d9e-ead6-4d80-93da-5dd098a9c90c"></a><a name="section-3.3"></a><p></p>
<h2><span class="Bold">3. Collagen Diseases</span></h2>
<p class="First">During an exacerbation or as maintenance therapy in selected cases of:</p>
<p><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span> Systemic <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span> (<span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>) Acute rheumatic carditis
                                    <br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_ed9b4f91-6000-4b6b-8056-918e3d6583c3"></a><a name="section-3.4"></a><p></p>
<h2><span class="Bold">4. Dermatologic Diseases</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span> <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span> Severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> Severe <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span>
                                    <br><br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_e758b15f-370f-4cd0-a59c-f86b5c4c0c65"></a><a name="section-3.5"></a><p></p>
<h2><span class="Bold">5. Allergic States</span></h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:</p>
<p>Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span> Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span> <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions
                                    <br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_904559e0-3e25-4491-b26f-bf52942383ef"></a><a name="section-3.6"></a><p></p>
<h2><span class="Bold">6. Ophthalmic Diseases</span></h2>
<p class="First">Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:</p>
<p><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span> <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> Allergic corneal marginal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> ophthalmicus <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span> and <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span> <span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span> Anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> Diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span> Sympathetic ophthalmia
                                    <br><br><br><br><br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_dc41fe34-e0b5-451f-81ae-b8d22f2f8072"></a><a name="section-3.7"></a><p></p>
<h2><span class="Bold">7. Respiratory Diseases</span></h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span>
                                    <br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_eb8f81d0-578f-4e02-96fd-09fc8561b7fe"></a><a name="section-3.8"></a><p></p>
<h2><span class="Bold">8. Hematologic Disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> Erythroblastopenia (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) Congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span>
                                    <br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_72539dff-8f79-4b41-af7f-fc2c034a3ea4"></a><a name="section-3.9"></a><p></p>
<h2><span class="Bold">9. Neoplastic Diseases</span></h2>
<p class="First">For palliative management of:</p>
<p><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span> of childhood
                                    <br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_b489f4cc-13e1-4df4-86c5-721fe23fd881"></a><a name="section-3.10"></a><p></p>
<h2><span class="Bold">10. Edematous States</span></h2>
<p class="First">To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathic type or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_54459453-a8dc-4fa0-a253-3f1fd81dc06f"></a><a name="section-3.11"></a><p></p>
<h2><span class="Bold">11. Gastrointestinal Diseases</span></h2>
<p class="First">To tide the patient over a critical period of the disease in:</p>
<p><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span> <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">Regional enteritis</span>
                                    <br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_141429e7-18c7-476b-845f-6f7035db38e3"></a><a name="section-3.12"></a><p></p>
<h2><span class="Bold">12. Nervous System</span></h2>
<p class="First">Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_d0d79c5a-7cb4-447e-9c5f-5b337eb3e16e"></a><a name="section-3.13"></a><p></p>
<h2><span class="Bold">13. Miscellaneous</span></h2>
<p class="First">Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy</p>
<p>Trichinosis with neurologic or myocardial involvement</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_90fae8e8-7cd5-4559-820d-5a164dcca3a2"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ea027c02-8417-4d2b-ae04-c32bfa7842df"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> with any pathogen including viral, bacterial, fungal, protozoan or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infections</span>, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.
                            <span class="Sup">1</span></p>
<p>These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used.
                            <span class="Sup">2</span></p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_28d2a111-de94-4583-9a43-5af1d3fc720d"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">Usage in pregnancy</span></h2>
<p class="First">Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<p>Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.</p>
<p>The use of hydrocortisone tablets in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
<p>Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals. Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_13f2ad9f-9daf-495f-b747-2e6ff0efdfeb"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_71738db9-f87d-43f6-bd8c-800b30e0a33f"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General Precautions</span></h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
<p>There is an enhanced effect of corticosteroids on patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>; and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.</p>
<p>Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See .)
                                    <span class="Bold"><a href="#LINK_5cb4a071-8518-4852-b600-577cad9fea83">DOSAGE AND ADMINISTRATION</a></span></p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d0e7b327-5818-4ada-aaef-9ba191b0cd42"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_b130e187-cca5-4c07-a888-a07ff93bfd3a"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Information for the Patient</span></h2>
<p class="First">Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_654679a5-4120-44e3-9c8a-8a889d907cce"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_2b417f66-72f0-4111-9330-ef0d6ce768a4"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span> <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients Potassium loss <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
                                    <br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_baf38009-90ed-491b-89ee-65b8853a2428"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Musculoskeletal</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">Steroid myopathy</span> Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span> <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span>, particularly of the Achilles tendon Vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones
                                    <br><br><br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_3f9a1e30-37a8-427f-b4b2-73df2866ca50"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Gastrointestinal</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> Ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.
                                    <br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_addf506c-9e72-494b-be27-fffb7d1085f7"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Dermatologic</span></h2>
<p class="First">Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing Thin fragile skin <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> Facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> May suppress reactions to skin tests
                                    <br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_bf0816c2-44f8-436b-949b-fdf5a79641da"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">Neurological</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually after treatment <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
                                    <br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_51ac1b09-f71a-4fc4-9fa1-3d5124392261"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Endocrine</span></h2>
<p class="First">Development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness Menstrual irregularities Decreased carbohydrate tolerance Manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics
                                    <br><br><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_3c4a9c0f-d87c-45e6-924e-4d3b4891c009"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">Ophthalmic</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span> <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span> <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>
                                    <br><br><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_4468262a-87b3-4f6f-b9cb-7d3518e5a91b"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">Metabolic</span></h2>
<p class="First">Negative nitrogen balance due to protein catabolism</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_5cb4a071-8518-4852-b600-577cad9fea83"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone tablets should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone tablets for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_408f02d9-2e8a-45b6-928b-bef066d56c85"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></span></h2>
<p class="First">In treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (20 mg of hydrocortisone is equivalent to 5 mg of prednisolone).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_d295fd71-1906-4a6d-a9ed-92d69a4413b7"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">NDC:68151-2269-1 in a PACKAGE of 1 TABLETS</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_668f80d4-f697-43c9-bb9e-acda9dfdb852"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<p class="First">Fekety R. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> associated with corticosteroids and immunosuppressive therapy. In:Gorbach SL, Bartlett JG, Blacklow NR, eds. Philadelphia: WB Saunders Company 1992:1050-1.
                            <span class="Sup">1</span><span class="Italics">Infectious Diseases.</span></p>
<p>Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. 1989:11(6):954-63.
                            <span class="Sup">2</span><span class="Italics">Rev Infect Dis</span></p>
<p>Manufactured by: Mikart, Inc. Atlanta, GA  30318 For: Lineage Therapeutics Horsham, PA 19044
                            <br><br><br><br><br></p>
<p>LB# 815-01</p>
<p>Code 1113D00                                                          Rev. January, 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_9d09f63b-d24d-4db4-ab8a-e45edc18fd2c"></a><a name="section-11"></a><p></p>
<h1>Hydrocortisone 20 MG TAB</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d4d2912e-d1e8-4b40-af88-59c87fa12318&amp;name=68151-2269.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROCORTISONE 		
					</strong><br><span class="contentTableReg">hydrocortisone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-2269(NDC:54505-333)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CP;333</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-2269-1</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040646</td>
<td class="formItem">03/30/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-2269)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b0f9b7ea-bac2-427d-92fa-4ccf1b149332</div>
<div>Set id: d4d2912e-d1e8-4b40-af88-59c87fa12318</div>
<div>Version: 2</div>
<div>Effective Time: 20130624</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
